Cefadroxil (DB01140): A Comprehensive Clinical and Pharmacological Monograph

Introduction and Drug Identification

Overview of Cefadroxil as a First-Generation Cephalosporin

Cefadroxil is a semi-synthetic, broad-spectrum antibiotic belonging to the first generation of the cephalosporin class.[1] It is administered orally and functions as a bactericidal agent, meaning it actively kills susceptible bacteria rather than merely inhibiting their growth.[3] Structurally, it is the para-hydroxy derivative of cephalexin, another prominent first-generation cephalosporin, and shares a similar spectrum of activity but possesses distinct pharmacokinetic advantages.[1] Cefadroxil is characterized as a long-acting, water-soluble compound, which contributes to its favorable dosing profile.[1]

The primary clinical utility of Cefadroxil lies in the treatment of mild to moderate infections caused by susceptible microorganisms. Its indications are well-established and include infections of the urinary tract, skin and skin structures, pharynx, and tonsils.[1] Like all β-lactam antibiotics, its mechanism of action involves the disruption of bacterial cell wall synthesis, a process essential for bacterial viability.[3] This targeted action makes it effective against a range of common pathogens.

In an era of increasing antimicrobial resistance, the judicious use of established agents like Cefadroxil is of paramount importance. It is critical to reserve its use for infections that are proven or strongly suspected to be caused by susceptible bacteria. This principle of antibiotic stewardship ensures the continued effectiveness of Cefadroxil and other antibacterial drugs for future generations and minimizes the selection pressure for resistant strains.[7] Cefadroxil is ineffective against viral infections such as the common cold or influenza, and its use in such cases provides no benefit to the patient while contributing to the global challenge of resistance.[3]

Chemical Identity and Physicochemical Properties

The precise identification of a pharmaceutical agent is foundational to its safe and effective use. Cefadroxil is a small molecule with the chemical formula .[1] Its average molecular weight is consistently reported as 363.39 g/mol (or 363.388 g/mol), with a monoisotopic mass of 363.088891359 Da.[1]

Its formal chemical structure is defined by the International Union of Pure and Applied Chemistry (IUPAC) name: (6R,7R)-7--3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.[10] This nomenclature precisely describes its core bicyclic cephem skeleton, the stereochemistry at its chiral centers, and the nature of its side chains, which are critical for its antibacterial activity and pharmacokinetic properties.

Cefadroxil is identified across various databases and regulatory systems by a unique set of identifiers. Its Chemical Abstracts Service (CAS) Registry Number is 50370-12-2, and its DrugBank Accession Number is DB01140.[1] It is known by numerous synonyms, including Cephadroxil, Cefadroxil anhydrous, Cefadroxilo, D-Cefadroxil, and p-hydroxycephalexine.[1] Commercially, it has been marketed under brand names such as Duricef and Ultracef.[5] A consolidated view of its key physicochemical properties is presented in Table 1.

Table 1: Physicochemical Properties of Cefadroxil

Property	Value	Source(s)
CAS Number	50370-12-2	1
Molecular Formula		1
Molecular Weight	363.39 g/mol	9
IUPAC Name	(6R,7R)-7--3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	10
Appearance	White to off-white or light orange crystalline powder or crystals	9
Solubility (Water)	9.17 mg/mL	12
Melting Point	Approximately 197°C (with decomposition)	12
Storage Conditions	Store under inert gas (Nitrogen or Argon) at 2–8 °C	12
Canonical SMILES	CC1=C(N2C@HC2=O)C(O)=O
InChI Key	BOEGTKLJZSQCCD-UEKVPHQBSA-N

Regulatory Status and Brand Formulations

Cefadroxil has a long history of clinical use, having first received approval from the United States Food and Drug Administration (FDA) in 1978. It is classified as an approved small molecule drug and is available for both human and veterinary use. In the United States, it is most commonly recognized by its former trademarked names, Duricef and Ultracef, though it is now widely available as a generic medication.

The medication is formulated exclusively for oral administration and is available in several dosage forms to accommodate different patient populations and dosing requirements. These include 500 mg capsules, 1 g tablets, and a powder for oral suspension, which is reconstituted to concentrations of 250 mg/5 mL and 500 mg/5 mL. The reconstituted suspension must be stored in a refrigerator and should be discarded after 14 days.

While Cefadroxil is well-established in the United States, its availability and branding can vary internationally. The provided documentation is heavily focused on the North American market. Searches for specific brand names currently marketed in other regions, such as Australia, did not yield definitive results within the available materials. For instance, information related to the Australian National Prescribing Service (NPS) or the Therapeutic Goods Administration (TGA) did not confirm a currently marketed Cefadroxil product, instead referencing other cephalosporins like cefuroxime or cephalexin. This underscores the importance of consulting local formularies and regulatory bodies for information on drug availability outside of the United States.

Pharmacology and Antimicrobial Spectrum

Molecular Mechanism of Action: Inhibition of Bacterial Cell Wall Synthesis

The bactericidal activity of Cefadroxil is a direct consequence of its ability to interfere with the synthesis of the bacterial cell wall. This mechanism is characteristic of all β-lactam antibiotics. The bacterial cell wall is a rigid, protective outer layer, primarily composed of a complex polymer called peptidoglycan, which provides structural integrity and protects the bacterium from osmotic lysis. Peptidoglycan consists of long glycan (sugar) chains cross-linked by short peptide (amino acid) bridges, forming a strong, mesh-like structure.

The final and crucial step in peptidoglycan synthesis is the cross-linking of these peptide bridges, a reaction catalyzed by a group of bacterial enzymes known as penicillin-binding proteins (PBPs). Cefadroxil, possessing a β-lactam ring that is structurally analogous to the D-Ala-D-Ala terminus of the peptidoglycan precursor, acts as a false substrate for these enzymes. It binds covalently to the active site of PBPs, leading to their irreversible acylation and inactivation.

By inhibiting the transpeptidase activity of PBPs, Cefadroxil effectively blocks the formation of the peptide cross-links. This disruption prevents the assembly of a functional, rigid peptidoglycan sacculus. The result is the synthesis of a structurally weak and defective cell wall that is unable to withstand the high internal osmotic pressure of the bacterial cytoplasm. This loss of structural integrity ultimately leads to cell swelling, membrane rupture, and bacterial cell lysis, accounting for the drug's potent bactericidal effect.

Pharmacodynamic Effects and Bactericidal Activity

The molecular inhibition of PBPs translates into a powerful pharmacodynamic effect: the active killing of bacteria. Cefadroxil's activity is most pronounced against rapidly dividing bacteria, as cell wall synthesis is most active during replication. The classification of Cefadroxil as a first-generation cephalosporin is defined by its specific spectrum of antimicrobial activity.

First-generation cephalosporins, including Cefadroxil, are particularly potent against Gram-positive bacteria. The cell wall of Gram-positive organisms consists of a thick, exposed layer of peptidoglycan, making the PBP targets readily accessible to the antibiotic. In contrast, Gram-negative bacteria possess a more complex cell envelope, which includes a thin peptidoglycan layer situated within the periplasmic space, protected by an outer membrane. This outer membrane can act as a permeability barrier, sometimes reducing the efficacy of certain β-lactam antibiotics against Gram-negative pathogens. Despite this, Cefadroxil retains clinically useful activity against several common Gram-negative species, particularly those that cause urinary tract infections.

In Vitro Spectrum of Activity and Resistance Mechanisms

The clinical utility of Cefadroxil is determined by its in vitro spectrum of activity against specific pathogens. It demonstrates excellent activity against many Gram-positive cocci. This includes Staphylococcus aureus (methicillin-susceptible strains, MSSA) and other staphylococci, as well as various streptococcal species, such as Streptococcus pyogenes (Group A β-hemolytic streptococci), the primary cause of streptococcal pharyngitis, and Streptococcus pneumoniae. Its activity against key Gram-negative organisms responsible for uncomplicated urinary tract infections includes

Escherichia coli, Proteus mirabilis, and Klebsiella species.

The potency of an antibiotic is quantified by its Minimum Inhibitory Concentration (MIC), the lowest concentration of the drug that prevents visible growth of a bacterium in vitro. This data is crucial for establishing clinical breakpoints and predicting therapeutic success. Table 2 summarizes available MIC data for Cefadroxil against medically significant microorganisms.

Table 2: Minimum Inhibitory Concentration (MIC) Data for Cefadroxil

Organism	MIC Range (μg/mL)	MIC₅₀ (μg/mL)	MIC₉₀ (μg/mL)	Source(s)
Staphylococcus aureus (MSSA)	1–2	2	4
Streptococcus pneumoniae	≤1 – >16	Not Available	Not Available
Escherichia coli	8	Not Available	Not Available

Note: MIC₅₀ and MIC₉₀ represent the concentrations at which 50% and 90% of isolates are inhibited, respectively.

A comparative analysis of MIC distributions for Cefadroxil and its parent compound, cephalexin, against a collection of 48 clinical MSSA isolates reveals nearly identical in vitro potency. Both drugs exhibited an MIC₅₀ of 2 μg/mL and an MIC₉₀ of 4 μg/mL against this panel of isolates. This finding is significant because it demonstrates that the choice between these two closely related agents should not be based on an assumption of superior antimicrobial strength. Instead, the clinical differentiation and rationale for selecting Cefadroxil over cephalexin are rooted in their differing pharmacokinetic profiles, particularly Cefadroxil's longer half-life, which allows for a more convenient dosing schedule.

Bacterial resistance to Cefadroxil and other β-lactam antibiotics is a significant clinical concern. The most prevalent mechanism of resistance is the production of β-lactamase enzymes. These enzymes hydrolytically cleave the amide bond in the β-lactam ring, rendering the antibiotic molecule inactive and unable to bind to its PBP targets. Other resistance mechanisms, though less common for first-generation cephalosporins, include modification of the PBP target site (as seen in methicillin-resistant

S. aureus, or MRSA) and alterations in outer membrane permeability or efflux pump expression in Gram-negative bacteria.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

Oral Bioavailability and Factors Affecting Absorption

Cefadroxil is formulated for oral administration and exhibits excellent bioavailability, being rapidly and almost completely absorbed from the gastrointestinal tract. Following a single oral dose, peak plasma concentrations (

) are typically achieved within 1.5 to 2.0 hours ( of 70-90 minutes). The peak concentrations achieved are dose-dependent. Studies have shown that single 500 mg and 1 g doses produce average

 values of approximately 16–18 μg/mL and 28–30 μg/mL, respectively.

A key clinical and practical advantage of Cefadroxil is that its rate and extent of absorption are not significantly affected by the concurrent administration of food. This property provides flexibility in dosing and distinguishes it from other oral cephalosporins. For example, studies in pediatric populations have demonstrated that while the absorption of cephalexin and cephradine can be diminished by a milk feed, the bioavailability of Cefadroxil remains unaffected. Although food does not impede its absorption, administering Cefadroxil with a meal is often recommended as a strategy to minimize potential gastrointestinal side effects, such as nausea or stomach upset, thereby improving patient tolerability and adherence.

Distribution in Body Tissues and Fluids

After absorption into the systemic circulation, Cefadroxil is widely distributed throughout the body. It achieves therapeutic concentrations in a variety of tissues and fluids, including pleural fluid, synovial fluid, and bone, making it suitable for treating infections in these locations. The apparent volume of distribution (

) has been reported to be approximately 0.31 L/kg, indicating distribution into total body water.

Cefadroxil exhibits low binding to plasma proteins, with approximately 20% of the drug being bound. This high fraction of unbound, pharmacologically active drug facilitates its penetration into tissues. The drug is known to cross the placental barrier, and it is also distributed into breast milk, albeit in low concentrations. Conversely, its penetration into certain compartments is limited. Distribution into bile is low, and it does not achieve significant concentrations in the cerebrospinal fluid (CSF), even in the presence of meningeal inflammation, precluding its use for treating meningitis.

Metabolic Profile and Elimination Pathways

Cefadroxil undergoes minimal to no metabolism in the body. It is primarily eliminated from the body via the kidneys. The overwhelming majority of an administered dose—over 90%—is excreted unchanged in the urine within 24 hours of administration. This renal elimination occurs through a combination of two processes: passive glomerular filtration and active tubular secretion.

The high efficiency of renal excretion results in exceptionally high concentrations of the active drug in the urine. Following a single 500 mg oral dose, peak urinary concentrations can reach approximately 1800 μg/mL. These concentrations far exceed the MIC values for common uropathogens, and therapeutic levels in the urine are maintained for 20 to 22 hours after a 1 g dose. This pharmacokinetic characteristic is the basis for its high efficacy in treating urinary tract infections.

Pharmacokinetic Parameters and Comparative Analysis

The elimination half-life () of Cefadroxil in adults with normal renal function is approximately 1.2 to 1.6 hours. This half-life is significantly longer than that of other commonly used oral cephalosporins, such as cephalexin (approximately 1.1 hours) and cefaclor (approximately 0.6 hours). This more sustained plasma concentration profile is a defining feature of Cefadroxil, allowing for less frequent dosing (once or twice daily) compared to the three or four times daily regimens required for agents with shorter half-lives. This enhanced convenience can lead to improved patient adherence.

Interestingly, the pharmacokinetics of Cefadroxil are not entirely linear across its full dosing range. While peak serum levels are proportional to the dose, a detailed study revealed that overall clearance mechanisms show signs of saturation at higher doses. The pharmacokinetics were linear in the 250 to 500 mg dose range. However, when the dose was increased from 500 mg to 1000 mg, the apparent serum clearance and true renal clearance decreased, and the area under the plasma concentration-time curve (AUC) increased disproportionately. This pattern is indicative of the saturation of a carrier-mediated process. Given that renal elimination involves both linear glomerular filtration and saturable active tubular secretion, this finding strongly suggests that the active renal tubular secretion pathway for Cefadroxil becomes saturated at doses exceeding 500 mg. This implies that at higher clinical doses (e.g., 1 g), patients experience a more-than-proportional increase in drug exposure, which may enhance efficacy but also underscores the importance of dosage adjustments in patients with compromised renal function.

In patients with renal impairment, the elimination half-life is dramatically prolonged, increasing to 20–24 hours in individuals with end-stage renal disease, necessitating significant dosage adjustments. Cefadroxil is, however, effectively cleared from the body by hemodialysis. A summary of key pharmacokinetic parameters is provided in Table 3.

Table 3: Key Pharmacokinetic Parameters of Cefadroxil

Parameter	Cefadroxil Value	Cephalexin Value (for comparison)	Source(s)
Time to Peak Concentration ()	1.5–2.0 hours	~1.0 hour
Peak Concentration () after 500 mg dose	~16–18 μg/mL	Similar to Cefadroxil
Volume of Distribution ()	0.31 L/kg	Not specified
Plasma Protein Binding	~20%	Not specified
Elimination Half-Life () (Adults)	1.2–1.6 hours	~1.1 hours
Elimination Half-Life () (Children)	1.3–1.8 hours	1.3–1.8 hours (similar)
Elimination Half-Life () (Renal Failure)	20–24 hours	Prolonged
Primary Excretion Route	>90% unchanged in urine	>90% unchanged in urine

Clinical Efficacy and Therapeutic Indications

Treatment of Urinary Tract Infections (UTIs)

Cefadroxil is a well-established and effective treatment for urinary tract infections. It is specifically indicated for UTIs, including uncomplicated cystitis, caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Klebsiella species. Its therapeutic efficacy in this setting is strongly supported by its pharmacokinetic profile. The drug is excreted in very high concentrations in the urine as an active, unchanged compound, ensuring that the site of infection is exposed to bactericidal levels of the antibiotic for a sustained period. The clinical use of Cefadroxil for this indication is further supported by post-marketing evidence, including a completed Phase 4 clinical trial that confirmed the bioequivalence of Cefadroxil formulations intended for the treatment of UTIs.

Treatment of Skin and Skin Structure Infections (SSSIs)

Another primary indication for Cefadroxil is the treatment of skin and skin structure infections. It is effective against the most common causative pathogens of these infections, namely staphylococci (e.g.,

S. aureus) and streptococci (e.g., S. pyogenes). Specific conditions for which it is used include impetigo and other common bacterial skin infections. Its efficacy for SSSIs has been validated in Phase 3 clinical trials.

Furthermore, Cefadroxil's favorable pharmacokinetic profile, particularly its longer half-life compared to cephalexin, makes it an attractive option for oral step-down therapy in pediatric patients with musculoskeletal infections such as osteomyelitis and septic arthritis. After initial intravenous therapy, transitioning to a convenient twice-daily oral regimen with Cefadroxil can facilitate earlier hospital discharge and improve adherence to the long course of treatment often required for these serious infections.

Treatment of Pharyngitis and Tonsillitis

Cefadroxil is indicated for the treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Eradication of this organism from the pharynx is crucial not only for resolving the acute symptoms of "strep throat" but also for preventing the subsequent development of non-suppurative sequelae, most notably acute rheumatic fever. To ensure bacteriological eradication and prevent these complications, a therapeutic course of Cefadroxil for streptococcal pharyngitis must be administered for a minimum of 10 days.

Prophylactic Use in Endocarditis Prevention

In addition to its therapeutic uses, Cefadroxil serves an important prophylactic role. It is recommended as an alternative agent for the prevention of infective endocarditis in specific at-risk patients who have a documented allergy to penicillin. This applies to individuals with certain high-risk cardiac conditions (e.g., prosthetic heart valves) who are undergoing dental procedures or manipulations of the upper respiratory tract that are associated with a risk of bacteremia. A single, high dose is administered shortly before the procedure to provide bactericidal coverage during the period of highest risk.

Summary of Supporting Clinical Trial Evidence

The clinical applications of Cefadroxil are substantiated by a body of evidence from clinical trials across various phases of development. Phase 1 studies have thoroughly characterized its pharmacokinetic profile in healthy adult volunteers and in specific patient populations, such as children with musculoskeletal infections, providing the foundational data for dosing recommendations.

Phase 3 trials have provided robust evidence of its clinical efficacy. Completed Phase 3 studies have confirmed its effectiveness in the treatment of bacterial infections, including staphylococcal skin infections. It is important to interpret trial data with precision. For example, one Phase 3 trial is listed as involving patients with Methicillin-Resistant

Staphylococcus aureus (MRSA). This information must be contextualized carefully, as first-generation cephalosporins, including Cefadroxil, are known to be clinically ineffective against MRSA due to its altered PBP target. The inclusion of MRSA in the trial's scope does not imply that Cefadroxil was used as a treatment for MRSA. It is far more probable that this was a comparative effectiveness trial for complex skin infections, where Cefadroxil was used as a comparator agent against other drugs with known MRSA activity (such as vancomycin or clindamycin, which are also listed in the trial record) or in the context of polymicrobial infections where Cefadroxil targeted other susceptible pathogens. This distinction is critical to prevent the dangerous misapplication of Cefadroxil in clinical practice for infections caused by MRSA.

Finally, Phase 4 post-marketing studies continue to support its use, such as the trial that established the bioequivalence of different Cefadroxil formulations for treating UTIs, ensuring that generic versions perform comparably to the original brand-name product.

Dosing and Administration Guidelines

Standard Dosing in Adult Populations

The oral dosage of Cefadroxil for adults is tailored to the specific indication and severity of the infection. All doses are expressed in terms of the anhydrous substance; it is noteworthy that 1.04 g of Cefadroxil monohydrate is equivalent to approximately 1 g of anhydrous Cefadroxil. The flexibility of once-daily or twice-daily administration for many conditions is a key advantage of its pharmacokinetic profile. Standard adult dosing regimens are summarized in Table 4.

Table 4: Standard Adult Dosing Regimens for Cefadroxil

Indication	Dosage	Frequency	Duration	Source(s)
Uncomplicated Urinary Tract Infections (e.g., Cystitis)	1 g or 2 g	As a single daily dose or divided q12h	Varies (e.g., 3-7 days)
Other/Complicated Urinary Tract Infections	1 g	q12h (2 g total per day)	Varies
Skin and Skin Structure Infections	1 g	As a single daily dose or divided q12h	Varies
Pharyngitis and/or Tonsillitis	1 g	As a single daily dose or divided q12h	10 days
Endocarditis Prophylaxis (Dental/Upper Respiratory Procedure)	2 g	Single dose 1 hour before procedure	Single dose

Dosing Considerations in Pediatric Patients

In the pediatric population, Cefadroxil dosing is calculated based on the patient's body weight to ensure appropriate exposure and efficacy. The general recommended daily dose for most susceptible infections is 30 mg/kg/day. This total daily dose is typically administered in two equally divided doses every 12 hours. For streptococcal pharyngitis, the 30 mg/kg/day dose can be given as a single daily dose to improve adherence. Maximum daily doses are in place to prevent toxicity; for UTIs, the maximum is 2 g per day, while for most SSSIs and pharyngitis, it is 1 g per day. For endocarditis prophylaxis, the pediatric dose is 50 mg/kg administered as a single dose one hour before the procedure, with a maximum dose not to exceed the adult dose of 2 g.

While effective, gastrointestinal tolerability in children can be dose-dependent. A pharmacokinetic study in pediatric patients observed a high incidence of vomiting (6 of 8 subjects) when an investigational high dose of 75 mg/kg was administered. When the dose was subsequently lowered to 50 mg/kg, the incidence of vomiting decreased significantly (1 of 6 subjects). This finding provides strong support for adhering to the standard 30 mg/kg/day dosing regimen in clinical practice. Furthermore, it was noted that gastrointestinal side effects like nausea and vomiting were less frequent when Cefadroxil was administered with food. This reinforces the clinical recommendation to give the medication with a meal or snack to enhance tolerability and ensure the full intended dose is absorbed.

Dosage Adjustments in Special Populations (e.g., Renal Impairment)

Cefadroxil is eliminated almost entirely by the kidneys, making dosage adjustment imperative in patients with impaired renal function to prevent drug accumulation, which can lead to increased risk of adverse effects, including central nervous system toxicity such as seizures. Dosage adjustments are generally recommended for patients with a creatinine clearance (

) rate of 50 mL/min or less.

The standard approach for adults involves administering a normal loading dose of 1 g, followed by a maintenance dose of 500 mg at extended intervals based on the degree of renal impairment. While different sources provide slightly varying thresholds for

, the general principle remains consistent. Care should also be taken when dosing elderly patients, as they are more likely to have age-related decreases in renal function. A summary of recommended dosage adjustments is provided in Table 5.

Table 5: Dosage Adjustments for Cefadroxil in Adult Renal Impairment

Creatinine Clearance (, mL/min)	Recommended Maintenance Dose and Interval (after 1 g loading dose)	Source(s)
>50	No adjustment needed
25–50	500 mg every 12 hours
10–25	500 mg every 24 hours
0–10	500 mg every 36 hours

Note: Clinicians should consult institutional guidelines, as specific  thresholds and dosing intervals may vary slightly between reference sources.

Safety and Tolerability Profile

Common and Infrequent Adverse Drug Reactions

Cefadroxil is generally a well-tolerated antibiotic. The most frequently reported adverse effects are related to the gastrointestinal system. These include diarrhea, nausea, vomiting, dyspepsia, and abdominal pain. These effects are typically mild to moderate in severity and can often be mitigated by administering the drug with food.

Other relatively common adverse reactions include hypersensitivity-related skin manifestations such as rash, urticaria (hives), and pruritus (itching). Fungal superinfections, resulting from the alteration of normal microbial flora, may also occur, leading to conditions like genital pruritus, vaginitis, or oral candidiasis (thrush).

Serious Adverse Events and Management

Although infrequent, Cefadroxil can be associated with serious adverse events that require immediate medical attention. One of the most significant is Clostridioides difficile-associated diarrhea (CDAD), also known as pseudomembranous colitis. This condition results from the overgrowth of the toxin-producing bacterium

C. difficile in the colon after the normal gut flora has been disrupted by antibiotic therapy. Symptoms can range from mild diarrhea to severe, persistent, watery, or bloody stools, accompanied by abdominal cramps and fever. CDAD can develop during treatment or, in some cases, up to two or more months after the antibiotic course has been completed. If CDAD is suspected, Cefadroxil should be discontinued, and appropriate management initiated.

Severe hypersensitivity reactions are another serious risk. While mild rashes are more common, severe reactions can include angioedema (swelling of the face, lips, tongue, and throat) and, in rare instances, life-threatening anaphylaxis. Other severe, albeit rare, adverse events that have been reported with Cefadroxil or other cephalosporins include severe cutaneous adverse reactions (SCARs) like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), serum sickness-like reactions, interstitial nephritis, and renal dysfunction. Hematologic abnormalities such as neutropenia, thrombocytopenia, agranulocytosis, and hemolytic or aplastic anemia have also been reported rarely. Seizures are a known, rare complication of cephalosporin therapy, particularly in patients with severe renal impairment whose dosage has not been appropriately reduced to account for decreased drug clearance.

Contraindications and Hypersensitivity Reactions

The absolute contraindication to the use of Cefadroxil is a known history of a severe allergic reaction (e.g., anaphylaxis) to Cefadroxil itself or to any other antibiotic within the cephalosporin class.

Significant caution is warranted when considering Cefadroxil for a patient with a history of penicillin allergy. Due to structural similarities in the β-lactam ring, there is a risk of immunological cross-reactivity between penicillins and cephalosporins. The historical estimate for this cross-reactivity is up to 10% in patients with a self-reported penicillin allergy. However, this risk is not uniform and requires nuanced clinical assessment. The likelihood of a cross-reaction is highest in patients who have experienced a severe, immediate, IgE-mediated reaction (e.g., anaphylaxis, urticaria, angioedema) to a penicillin. In contrast, the risk is considerably lower in patients who have only experienced a mild, delayed rash. In fact, Cefadroxil is often used as a prophylactic agent in selected penicillin-allergic patients, and has been administered safely in this population. The decision to prescribe Cefadroxil to a penicillin-allergic patient must involve a careful evaluation of the nature and severity of the previous reaction versus the potential benefit of the antibiotic.

Warnings, Precautions, and Use in Pregnancy and Lactation

Several precautions should be observed when prescribing Cefadroxil. It should be used with caution in individuals with a history of gastrointestinal disease, particularly colitis, as antibiotics can exacerbate this condition. As with all antibiotics, prolonged use of Cefadroxil may lead to the overgrowth of non-susceptible organisms, such as fungi or resistant bacteria, resulting in a superinfection. To combat the development of antimicrobial resistance, Cefadroxil should only be prescribed when there is a proven or strongly suspected bacterial infection.

With respect to use in special populations:

• Pregnancy: Cefadroxil is assigned to FDA Pregnancy Category B. While reproduction studies in animals have not demonstrated a risk to the fetus, there is a lack of adequate and well-controlled studies in pregnant women. Therefore, Cefadroxil should be used during pregnancy only when there is a clear clinical need and the potential benefits outweigh the potential risks.
• Lactation: Cefadroxil is known to be excreted into human breast milk, but in low concentrations. The relative infant dose has been calculated to be low (2.6% of the maternal dose), and adverse effects in nursing infants are considered unlikely. Nevertheless, caution should be exercised when administering Cefadroxil to a nursing mother.

Clinically Significant Drug Interactions

Pharmacokinetic Interactions Affecting Renal Clearance

The most prominent pharmacokinetic drug interactions involving Cefadroxil are related to its primary route of elimination via active tubular secretion in the kidneys. A large number of these interactions can be explained by a unifying mechanism: competition for the Organic Anion Transporter (OAT) system in the renal proximal tubules. Cefadroxil, as an anionic drug, is a substrate for these transporters.

Co-administration of Cefadroxil with other drugs that are also substrates or inhibitors of this pathway can lead to clinically significant interactions. For instance, probenecid is a classic inhibitor of renal tubular secretion that, when given with Cefadroxil, can block its excretion, leading to higher and more prolonged plasma concentrations of the antibiotic.

Conversely, Cefadroxil can inhibit the renal clearance of numerous other anionic drugs, potentially increasing their plasma levels and risk of toxicity. This is the mechanism underlying its interaction with many nonsteroidal anti-inflammatory drugs (NSAIDs) like aceclofenac, as well as antivirals like acyclovir and abacavir, and other medications such as allopurinol and pemetrexed. Understanding this common pathway allows clinicians to anticipate potential interactions with a wide range of acidic drugs beyond those explicitly listed in drug interaction tables.

Pharmacodynamic Interactions and Additive Toxicities

Pharmacodynamic interactions occur when drugs with similar or opposing effects are co-administered. A key concern with Cefadroxil is the potential for additive nephrotoxicity. The risk of kidney damage can be increased when Cefadroxil is used concurrently with other potentially nephrotoxic agents. This includes aminoglycoside antibiotics, potent diuretics, certain antiviral medications like adefovir dipivoxil, and NSAIDs. Careful monitoring of renal function is advised when such combinations are unavoidable.

Cefadroxil may also enhance the anticoagulant effect of vitamin K antagonists like acenocoumarol or warfarin. The proposed mechanism involves the alteration of the gut microbiome, which is responsible for synthesizing vitamin K. By suppressing these bacteria, Cefadroxil can lead to a vitamin K-deficient state, thereby potentiating the effect of the anticoagulant and increasing the risk of bleeding. Close monitoring of the International Normalized Ratio (INR) is recommended in patients receiving this combination.

Interactions with Vaccines and Laboratory Assays

Cefadroxil can interfere with the efficacy of certain vaccines. Specifically, because it is an antibacterial agent, it can inhibit the replication of the attenuated bacteria used in live bacterial vaccines. This can result in a diminished immune response and inadequate protection. Therefore, administration of live bacterial vaccines, such as the oral typhoid vaccine, BCG vaccine, and live cholera vaccine, is generally contraindicated or should be avoided during and for a period following Cefadroxil therapy.

Cefadroxil can also cause interference with certain laboratory tests. It has been reported to cause false-positive results for glucose in the urine when tests utilizing the cupric sulfate reduction method (e.g., Clinitest) are used. Patients with diabetes who monitor their urinary glucose should be advised to use tests based on the glucose oxidase method (e.g., Clinistix, Tes-Tape) to avoid inaccurate readings. Additionally, like other cephalosporins, Cefadroxil can lead to the development of a positive direct Coombs' test, which can interfere with cross-matching of blood. A summary of the most clinically relevant drug interactions is presented in Table 6.

Table 6: Summary of Key Drug-Drug Interactions with Cefadroxil

Interacting Agent/Class	Mechanism / Effect	Clinical Management	Source(s)
Probenecid	Inhibition of renal tubular secretion, leading to increased and prolonged Cefadroxil serum levels.	Avoid concurrent use if possible. If used, monitor for Cefadroxil toxicity.
Nephrotoxic Agents (e.g., NSAIDs, Aminoglycosides)	Additive nephrotoxicity, increasing the risk of kidney injury.	Avoid concurrent use if possible. If necessary, monitor renal function (e.g., serum creatinine) closely.
Anticoagulants (Vitamin K Antagonists)	Potential potentiation of anticoagulant effect, increasing the risk of bleeding.	Monitor INR closely and adjust anticoagulant dose as needed. Counsel patient on signs of bleeding.
Live Bacterial Vaccines (e.g., Typhoid, Cholera, BCG)	Decreased vaccine efficacy due to inhibition of bacterial replication.	Avoid co-administration. Administer vaccine only after the antibiotic course is fully completed.
Other Anionic Drugs (e.g., Acyclovir, Pemetrexed)	Competition for renal tubular secretion, potentially increasing levels of the co-administered drug.	Be aware of potential for increased toxicity of the co-administered drug. Monitor for adverse effects.

Conclusion and Clinical Synopsis

Summary of Cefadroxil's Therapeutic Profile

Cefadroxil is a well-established, effective, and generally well-tolerated first-generation oral cephalosporin antibiotic. Its clinical value is anchored in its reliable bactericidal activity against a spectrum of common Gram-positive and select Gram-negative pathogens that are frequently implicated in community-acquired infections of the skin, urinary tract, and pharynx.

While its in vitro potency against key pathogens like MSSA is comparable to its parent compound, cephalexin, Cefadroxil's defining therapeutic advantage lies in its superior pharmacokinetic profile. Characterized by a longer elimination half-life and absorption that is unaffected by food, Cefadroxil allows for more convenient once or twice-daily dosing regimens. This simplified schedule can significantly enhance patient adherence, which is a critical determinant of therapeutic success, particularly in pediatric populations and for treatment courses requiring extended duration, such as the 10-day regimen for streptococcal pharyngitis.

Key Considerations for Clinical Practice and Recommendations

Based on a comprehensive review of its pharmacological, clinical, and safety data, the following recommendations are provided to guide the optimal use of Cefadroxil in clinical practice:

1. Leverage the Dosing Advantage for Adherence: Clinicians should consider Cefadroxil as a preferred first-generation cephalosporin in scenarios where adherence to a more frequent dosing schedule (e.g., three or four times daily for cephalexin) may be challenging. Its once or twice-daily regimen is particularly advantageous for pediatric patients and for ensuring completion of 10-day treatment courses.
2. Prioritize Renal Function Assessment: Due to its near-exclusive reliance on renal clearance, it is imperative to assess renal function by estimating creatinine clearance before initiating therapy. In patients with a  below 50 mL/min, dosage adjustments are mandatory to prevent drug accumulation and the associated risk of toxicity, including seizures. This is especially critical in elderly patients, in whom a decline in renal function is common.
3. Promote Antibiotic Stewardship: To preserve its efficacy and combat the global threat of antimicrobial resistance, Cefadroxil should be prescribed responsibly. Its use must be reserved for infections with a proven or strongly suspected susceptible bacterial etiology. It is ineffective against viral illnesses, and patient education on this point is crucial.
4. Emphasize Patient Counseling: Effective patient counseling is essential for safety and efficacy. Patients should be instructed on the importance of completing the full prescribed course of therapy, even if symptoms improve early. They should be advised that taking Cefadroxil with food can minimize gastrointestinal discomfort. Critically, patients must be educated to recognize and immediately report symptoms of a severe allergic reaction (e.g., hives, difficulty breathing, swelling of the face or throat) or Clostridioides difficile-associated diarrhea (e.g., severe, watery diarrhea and abdominal cramps).

Works cited

1. Cefadroxil: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 5, 2025, https://go.drugbank.com/drugs/DB01140
2. cefadroxil monograph - Texas Health and Human Services, accessed October 5, 2025, https://www.hhs.texas.gov/sites/default/files/documents/cefadroxil-monograph.pdf
3. Cefadroxil (oral route) - Side effects & dosage - Mayo Clinic, accessed October 5, 2025, https://www.mayoclinic.org/drugs-supplements/cefadroxil-oral-route/description/drg-20073247
4. Cefadroxil - Wikipedia, accessed October 5, 2025, https://en.wikipedia.org/wiki/Cefadroxil
5. Cefadroxil: MedlinePlus Drug Information, accessed October 5, 2025, https://medlineplus.gov/druginfo/meds/a682730.html
6. Cephalosporins - StatPearls - NCBI Bookshelf, accessed October 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK551517/
7. Cefadroxil Capsules USP 500 mg - DailyMed, accessed October 5, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d433e4e8-9f38-405e-ac80-bc8dfcba0649&type=display
8. Cefadroxil (Cefadroxil Hemihydrate): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 5, 2025, https://www.rxlist.com/cefadroxil-drug.htm
9. Cefadroxil analytical standard 50370-12-2 - Sigma-Aldrich, accessed October 5, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/c7020
10. CAS RN 50370-12-2 - Fisher Scientific, accessed October 5, 2025, https://www.fishersci.fi/fi/en/browse/cas/50370-12-2
11. cefadroxil | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 5, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4831
12. CEFADROXIL | 50370-12-2 - ChemicalBook, accessed October 5, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1203657.htm
13. Cefadroxil: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 5, 2025, https://www.rxlist.com/cefadroxil/generic-drug.htm
14. cefadroxil | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 5, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=4831
15. Cefadroxil Capsules USP - Lupin, accessed October 5, 2025, https://www.lupin.com/US/product/cefadroxil-capsules-usp
16. Duricef, Ultracef (cefadroxil) dosing, indications, interactions ..., accessed October 5, 2025, https://reference.medscape.com/drug/duricef-ultracef-cefadroxil-342489
17. cefadroxil: Dosing, contraindications, side effects, and pill pictures - epocrates online, accessed October 5, 2025, https://www.epocrates.com/online/drugs/5/cefadroxil
18. Cefadroxil - WikEM, accessed October 5, 2025, https://wikem.org/wiki/Cefadroxil
19. Duricef - Drug Summary, accessed October 5, 2025, https://www.pdr.net/drug-summary/Cefadroxil-Capsules-cefadroxil-1543
20. Pharmacor Cefuroxime - NPS MedicineWise, accessed October 5, 2025, https://www.nps.org.au/medicine-finder/pharmacor-cefuroxime-tablets
21. CEPHALEXIN-WGR cefalexin 500mg capsule blister pack (432150), accessed October 5, 2025, https://www.tga.gov.au/resources/artg/432150
22. What is the mechanism of Cefadroxil? - Patsnap Synapse, accessed October 5, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-cefadroxil
23. 65115 Cefadroxil Bioequivalence Review - accessdata.fda.gov, accessed October 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/anda/2003/65115_Cefadroxil_Bioeqr.pdf
24. Cefadroxil Comparable to Cephalexin: Minimum Inhibitory Concentrations among Methicillin-Susceptible Staphylococcus aureus Isolates from Pediatric Musculoskeletal Infections - PMC, accessed October 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9431593/
25. Pharmacokinetics of cefadroxil after oral administration in humans - PubMed, accessed October 5, 2025, https://pubmed.ncbi.nlm.nih.gov/7073267/
26. Comparative pharmacokinetics of cefadroxil, cefaclor, cephalexin and cephradine in infants and children, accessed October 5, 2025, https://academic.oup.com/jac/article-pdf/10/suppl_B/27/2236247/10-suppl_B-27.pdf
27. Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed October 5, 2025, https://journals.asm.org/doi/10.1128/aac.00182-24
28. Cefadroxil Completed Phase 4 Trials for Urinary Tract Infection Other | DrugBank Online, accessed October 5, 2025, https://go.drugbank.com/drugs/DB01140/clinical_trials?conditions=DBCOND0024122&phase=4&purpose=other&status=completed
29. Cefadroxil Completed Phase 3 Trials for Staphylococcal Skin Infections / Methicillin Resistant Staphylococcus Aureus (MRSA) / Bacterial Infections Treatment - DrugBank, accessed October 5, 2025, https://go.drugbank.com/drugs/DB01140/clinical_trials?conditions=DBCOND0027917%2CDBCOND0030654%2CDBCOND0032713&phase=3&purpose=treatment&status=completed
30. Cefadroxil Completed Phase 1 Trials for Osteomyelitis / Septic Arthritis / Pyomyositis Basic Science | DrugBank Online, accessed October 5, 2025, https://go.drugbank.com/drugs/DB01140/clinical_trials?conditions=DBCOND0014303%2CDBCOND0014780%2CDBCOND0037400&phase=1&purpose=basic_science&status=completed
31. Cefadroxil | Saint Luke's Health System, accessed October 5, 2025, https://www.saintlukeskc.org/health-library/cefadroxil
32. cefadroxil 500 mg capsule - Kaiser Permanente, accessed October 5, 2025, https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.cefadroxil-500-mg-capsule.216223
33. Cefadroxil Completed Phase 1 Trials for Healthy Volunteers (HV) Basic Science - DrugBank, accessed October 5, 2025, https://go.drugbank.com/drugs/DB01140/clinical_trials?conditions=DBCOND0114743&phase=1&purpose=basic_science&status=completed
34. Cefadroxil - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed October 5, 2025, https://www.pediatriconcall.com/drugs/cefadroxil/375
35. CEFADROXIL - ORAL (Duricef) side effects, medical uses, and drug interactions., accessed October 5, 2025, https://www.medicinenet.com/cefadroxil-oral/article.htm
36. Side Effects of Cefadroxil: Interactions & Warnings - MedicineNet, accessed October 5, 2025, https://www.medicinenet.com/side_effects_of_cefadroxil/side-effects.htm
37. Cefadroxil: Uses, Side Effects, Dosage & Interactions - Apollo Hospitals, accessed October 5, 2025, https://www.apollohospitals.com/medicines/cefadroxil
38. Cefadroxil: Uses, Side Effects, Dosage & Reviews - GoodRx, accessed October 5, 2025, https://www.goodrx.com/cefadroxil/what-is
39. go.drugbank.com, accessed October 5, 2025, https://go.drugbank.com/drugs/DB01140#:~:text=The%20risk%20or%20severity%20of,Cefadroxil%20is%20combined%20with%20Aceclofenac.&text=Acemetacin-,The%20risk%20or%20severity%20of%20nephrotoxicity%20can%20be,Cefadroxil%20is%20combined%20with%20Acemetacin.&text=The%20risk%20or%20severity%20of%20bleeding%20can%20be,Cefadroxil%20is%20combined%20with%20Acenocoumarol.
40. Cefadroxil – Health Information Library - PeaceHealth, accessed October 5, 2025, https://www.peacehealth.org/medical-topics/id/hn-10000210